- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03397706
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
March 1, 2024 updated by: Viracta Therapeutics, Inc.
A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory EBV+ lymphomas.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir is safe, determine the side effect profile, and to determine whether this therapy may help patients with EBV-related lymphomas.
The study has two phases.
Goals of the first phase include determining a safe and tolerable dose that can be administered in phase 2. Goals of the second phase include further evaluating the safety and tolerability of VRx-3996 in combination with valganciclovir, evaluating how the drugs are metabolized in the body, evaluating response rates and other exploratory objectives that will help the researchers evaluate how these drugs work in the body.
Participants will receive daily oral doses of the two study drugs and will have multiple study visits where they will have blood collected, physical examinations, and other medical monitoring.
Following completion of the Ph2, the study will enroll additional patients into a PK cohort to investigate the PK parameters of the tablet formulation.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robert McRae, Vice President, Operations
- Phone Number: 858-400-8470
- Email: ClinicalTrials@Viracta.com
Study Locations
-
-
BA
-
Salvador, BA, Brazil, 40110-090
- Centro de Hematologia e Oncologia da Bahia (CEHON)
-
-
PE
-
Recife, PE, Brazil, 50040-000
- Hospital de Cancer de Pernambuco (HCP)
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil
- Hospital do Câncer Mãe de Deus
-
-
SP
-
São Paulo, SP, Brazil, 08270-070
- Hospital Santa Marcelina
-
São Paulo, SP, Brazil, 01321-001
- Real e Benemérita Associação Portuguesa de Beneficência
-
São Paulo, SP, Brazil, 05403-000
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
-
-
-
-
California
-
Los Angeles, California, United States, 90033
- USC Norris Comprehensive Cancer Center
-
Los Angeles, California, United States, 90404
- University of California, Los Angeles
-
Orange, California, United States, 92868
- UC Irvine Chao Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Cancer Pavilion
-
-
Florida
-
Orange City, Florida, United States, 32763
- Mid Florida Hematology and Oncology Center
-
Weeki Wachee, Florida, United States, 34607
- ASCLEPES Research Centers
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute, Emory University
-
Augusta, Georgia, United States, 30912
- Georgia Cancer Center at Augusta University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Feinberg School of Medicine
-
Chicago, Illinois, United States, 60612
- Ruth M Rothstein CORE Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46237
- Indiana Blood and Marrow Transplantation
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- The University of Kansas Cancer Center and Medical Pavilion
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Montana
-
Billings, Montana, United States, 59102
- St. Vincent Healthcare Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center at Hackensack UMC
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10065
- Weill Cornell Medical College - New York Presbyterian Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Sammons Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Relapsed/refractory, pathologically confirmed EBV+ lymphoid malignancy or lymphoproliferative disease
- Absence of available therapy with reasonable likelihood of cure or significant clinical benefit
- Adequate hematologic, hepatic and renal function as defined by laboratory assessment
Key Exclusion Criteria:
- Known primary CNS lymphoma
- Known CNS metastases or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks
- Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- Refractory graft versus host disease (GvHD) not responding to treatment
- Known active hepatitis B virus infection
- Circulating hepatitis C virus on qPCR
- Known history of HHV-6 chromosomal integration
- Known history of HIV infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b Dose Escalation
VRx-3996 (cohort 1) and valganciclovir VRx-3996 (cohort 2) and valganciclovir VRx-3996 (cohort 3) and valganciclovir VRx-3996 (cohort 4) and valganciclovir VRx-3996 (cohort 5) and valganciclovir |
Taken orally once or twice daily
Other Names:
Taken orally once or twice daily
|
Experimental: Phase 2 Dose Expansion
VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
|
Taken orally once or twice daily
Other Names:
Taken orally once or twice daily
|
Experimental: PK Cohort
Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D
|
Taken orally once or twice daily
Other Names:
Taken orally once or twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events and changes in clinical safety laboratory values in Dose Escalation and Cohort Expansion
Time Frame: Up to approximately 2 years
|
Determination of a safe and tolerable Recommended Phase 2 Dose (RP2D)
|
Up to approximately 2 years
|
Incidence of Dose Limiting Toxicities in Dose Escalation and Cohort Expansion
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
ORR as measured by stable disease (SD), partial response (PR), and complete response (CR) by radiographic assessment
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Single-dose and steady-state Cmax of VRx-3996 and valganciclovir
Time Frame: Through Cycle 2 Day 15 (each cycle is 28 days)
|
PK assessment of both VRx-3996 and valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1 and C2D1 and pre-dose and at hour 2 on C1D2 ,C1D15, and C2D15
|
Through Cycle 2 Day 15 (each cycle is 28 days)
|
Single-dose and steady-state AUC of VRx-3996 and valganciclovir
Time Frame: Through Cycle 2 Day 15 (each cycle is 28 days)
|
PK assessment of both VRx-3996 and valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1 and C2D1 and pre-dose and at hour 2 on C1D2 ,C1D15, and C2D15
|
Through Cycle 2 Day 15 (each cycle is 28 days)
|
Steady-state elimination half-life of VRx-3996 and valganciclovir
Time Frame: Through Cycle 2 Day 15 (each cycle is 28 days)
|
PK assessment of both VRx-3996 and valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1 and C2D1 and pre-dose and at hour 2 on C1D2, C1D15, and C2D15
|
Through Cycle 2 Day 15 (each cycle is 28 days)
|
Time to response
Time Frame: Approximately 6 months
|
The time from the start of first study drug administration to the first overall tumor response observed for subjects who achieved a CR or PR
|
Approximately 6 months
|
Duration of response
Time Frame: Up to approximately 2 years
|
The time interval (days) from date of the first overall response (CR or PR; achieved after study drug administration) to the date of disease progression
|
Up to approximately 2 years
|
Progression-free survival
Time Frame: Up to approximately 2 years
|
The interval between the date of first study drug administration and the date of PD or death, whichever is first reported
|
Up to approximately 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jill DeFratis Robinson, Viracta Therapeutics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 29, 2018
Primary Completion (Actual)
April 1, 2023
Study Completion (Actual)
May 4, 2023
Study Registration Dates
First Submitted
December 20, 2017
First Submitted That Met QC Criteria
January 10, 2018
First Posted (Actual)
January 12, 2018
Study Record Updates
Last Update Posted (Estimated)
March 5, 2024
Last Update Submitted That Met QC Criteria
March 1, 2024
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VT3996-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoproliferative Disorders
-
A.O. Ospedale Papa Giovanni XXIIICompletedPost-transplant Lymphoproliferative Disease (PTLD) | Non BurkittItaly
-
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbHCompletedPosttransplant Lymphoproliferative DisorderGermany
-
Becton, Dickinson and CompanyCompletedChronic Lymphoproliferative Diseases (CLPD)United States, Switzerland, Spain, United Kingdom, Portugal
-
Geron CorporationCompletedChronic Lymphoproliferative DiseasesUnited States
-
Becton, Dickinson and CompanyRecruitingChronic Lymphoproliferative Diseases (CLPD)Switzerland, United States, Portugal, Spain
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedLymphoproliferative DisorderUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Lymphoproliferative Disorder | Refractory Lymphoproliferative DisorderUnited States
-
Deepa JagadeeshTerminatedPost-transplant Lymphoproliferative DisorderUnited States
-
Charite University, Berlin, GermanyTerminatedPost-transplantation Lymphoproliferative DisorderAustralia, France, Germany, Sweden
-
Hospices Civils de LyonCompleted
Clinical Trials on VRx-3996
-
Viracta Therapeutics, Inc.RecruitingNasopharyngeal Carcinoma | EBV-Related Gastric Carcinoma | EBV-Related Leiomyosarcoma | EBV Related Carcinoma | EBV-Related SarcomaUnited States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Australia, Canada, Malaysia
-
Centre Hospitalier Universitaire de Saint EtienneCompletedLabor Pain | Delivery ProblemFrance
-
Chroma TherapeuticsCompletedSafety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid TumoursSolid TumorNetherlands, United Kingdom